Skip to main content
. Author manuscript; available in PMC: 2021 Jun 10.
Published in final edited form as: Thorax. 2010 Jun;65(6):480–485. doi: 10.1136/thx.2009.122002

Table 1.

Characteristics of the study subjects by gender, Bergen, Norway 2003–2005

Subjects with COPD
Subjects without COPD
Male Female Male Female
n = 583 (61.1%) n = 371 (38.9%) p Value n = 479 (50.2%) n = 476 (49.8%) p Value
Age, years 66.2 (10.2) 64.4 (9.8) 0.009 56.3 (9.9) 54.8 (9.4) 0.013
Smoking, %
 Ex- 55.6 49.1 0.049 64.3 53.6 0.001
 Current 44.4 50.9 35.7 46.4
Pack-years, median (25, 75*) 32.2 (22.5, 44.9) 24.0 (17.2, 34.1) <0.001 18.0 (10.5, 28.0) 14.2 (8.0, 23.3) <0.001
Age started smoking, years 17.4 (3.7) 20.5 (6.2) <0.001 17.7 (3.8) 19.2 (5.6) <0.001
Self-reported asthma, % 42.7 61.6 <0.001 6.3 12.8 0.001
Bronchodilator response 7.4 (13.1) 8.5 (13.6) 0.229 3.1 (4.0) 3.8 (4.5) 0.015
Occupational exposure, % 79.4 45.5 <0.001 66.7 32.4 <0.001
Educational level, %
 Primary 29.9 33.6 0.008 16.5 12.2 0.100
 Secondary 56.3 59.0 57.1 62.8
 University 13.9 7.4 26.4 25.0
Post-BD spirometry
 FEV1% predicted 51.2 (17.8) 50.3 (16.7) 0.405 94.4 (8.9) 95.4 (9.2) 0.093
 FEV1/FVC 0.5 (0.1) 0.5 (0.1) 0.168 0.8 (0.04) 0.8 (0.04) 0.225
GOLD stage, %
 2 55.1 55.5 0.971
 3 30.4 30.5
 4 14.6 14.0

Unless otherwise noted, data are presented as means (SD).

*

25th and 75th percentiles.

FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; post-BD, postbronchodilator.